Ipsen Provides COVID-19 Update
PARIS--(BUSINESS WIRE)-- Regulatory News:
IPSEN S.A.S. (Euronext: IPN; ADR: IPSEY) provided today an update related to the impact of the Covid-19 pandemic on its global business which is affected in varying degrees in the countries impacted by the coronavirus, with very different and evolving situations from one country to another.
Since the start of the health crisis, Ipsen has taken the necessary measures to ensure the safety of its employees around the world and to focus on business continuity so that it can provide patients with access to its medicines. As part of these preventive measures, and in line with local health authorities’ guidance, Ipsen has instituted a global travel ban as well as home office policies where appropriate. Ipsen has also paused in-person interactions with healthcare professionals in several markets where its field-based employees are working from home using technology to interact virtually with healthcare professionals (HCPs).
Ipsen sees a limited financial impact today given its resilient product portfolio comprised mostly of diversified treatments with highly-differentiating and long-acting formulations for critical chronic conditions. However, given the general economic slowdown, its performance year-to-date in China, reduced interactions with healthcare professionals and the uncertainty about the duration and scale of the health crisis, Ipsen has decided to suspend its 2020 financial guidance announced in February as it is not possible at this stage to quantify its impact on the Group’s financial statements. Further updates will be provided as the situation evolves.
“Our teams across the world share one essential objective: ensuring access to our medicines for patients,” said Aymeric Le Chatelier, Chief Executive Officer and Chief Financial Officer of Ipsen. “We are working closely with our national and international suppliers to monitor the provision of goods and services, with the goal of continuing our operations as seamlessly as possible. At this time, we do not anticipate any supply shortages.”
The Group has a very solid financial position with sound cash and financing in place. Ipsen confirms its proposed distribution of €1.00 per share for the 2019 financial year.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com
Ipsen—Cautionary Note Regarding Forward-Looking Statements
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes", "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2018 Registration Document available on its website (www.ipsen.com).
Christian Marcoux, M.Sc.
Senior Vice President, Global Communications
+33 (0)1 58 33 67 94
Senior Director, France Hub, Global Communications
+33 (0) 1 58 33 58 96
Vice President, Investor Relations
+44 (0) 1753 627721
Investor Relations Manager
+33 (0)1 58 33 51 04